Target Price | €51.00 |
Price | €43.20 |
Potential | 18.06% |
Number of Estimates | 22 |
22 Analysts have issued a price target Fresenius Medical Care 2026 . The average Fresenius Medical Care target price is €51.00. This is 18.06% higher than the current stock price. The highest price target is €65.10 50.69% , the lowest is €24.44 43.42% . | |
A rating was issued by 25 analysts: 11 Analysts recommend Fresenius Medical Care to buy, 10 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Fresenius Medical Care stock has an average upside potential 2026 of 18.06% . Most analysts recommend the Fresenius Medical Care stock at Purchase. |
24 Analysts have issued a sales forecast Fresenius Medical Care 2025 . The average Fresenius Medical Care sales estimate is €19.7b . This is 1.05% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €20.9b 6.91% , the lowest is €18.7b 4.38% .
This results in the following potential growth metrics:
2024 | €19.3b | 0.61% |
---|---|---|
2025 | €19.7b | 2.01% |
2026 | €20.3b | 3.11% |
2027 | €21.2b | 4.44% |
2028 | €22.4b | 5.46% |
2029 | €23.4b | 4.48% |
2030 | €24.9b | 6.38% |
2031 | €25.2b | 1.05% |
2032 | €26.1b | 3.57% |
21 Analysts have issued an Fresenius Medical Care EBITDA forecast 2025. The average Fresenius Medical Care EBITDA estimate is €3.7b . This is 21.58% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €4.1b 37.00% , the lowest is €2.7b 11.90% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €3.0b | 0.73% |
---|---|---|
2025 | €3.7b | 21.57% |
2026 | €3.9b | 7.19% |
2027 | €4.1b | 4.74% |
2028 | €4.1b | 0.80% |
2029 | €4.4b | 5.29% |
2030 | €4.8b | 9.71% |
2031 | €5.0b | 5.08% |
2032 | €5.2b | 3.90% |
2024 | 15.56% | 0.12% |
---|---|---|
2025 | 18.54% | 19.17% |
2026 | 19.28% | 3.99% |
2027 | 19.33% | 0.26% |
2028 | 18.48% | 4.40% |
2029 | 18.62% | 0.76% |
2030 | 19.20% | 3.11% |
2031 | 19.97% | 4.01% |
2032 | 20.04% | 0.35% |
23 Fresenius Medical Care Analysts have issued a net profit forecast 2025. The average Fresenius Medical Care net profit estimate is €1.1b . This is 71.25% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €1.3b 91.02% , the lowest is €1.0b 58.57% .
This results in the following potential growth metrics and future Net Margins:
2024 | €538m | 7.80% |
---|---|---|
2025 | €1.1b | 108.98% |
2026 | €1.2b | 9.64% |
2027 | €1.4b | 17.24% |
2028 | €1.6b | 11.53% |
2029 | €1.8b | 10.69% |
2030 | €2.2b | 21.57% |
2031 | €2.1b | 5.39% |
2032 | €2.2b | 7.64% |
2024 | 2.78% | 8.45% |
---|---|---|
2025 | 5.70% | 104.89% |
2026 | 6.06% | 6.32% |
2027 | 6.80% | 12.21% |
2028 | 7.20% | 5.88% |
2029 | 7.62% | 5.83% |
2030 | 8.71% | 14.30% |
2031 | 8.16% | 6.31% |
2032 | 8.48% | 3.92% |
23 Analysts have issued a Fresenius Medical Care forecast for earnings per share. The average Fresenius Medical Care EPS is €3.83 . This is 70.98% higher than earnings per share in the financial year 2024. The highest EPS forecast is €4.27 90.63% , the lowest is €3.55 58.48% .
This results in the following potential growth metrics and future valuations:
2024 | €1.83 | 7.65% |
---|---|---|
2025 | €3.83 | 109.29% |
2026 | €4.20 | 9.66% |
2027 | €4.92 | 17.14% |
2028 | €5.49 | 11.59% |
2029 | €6.08 | 10.75% |
2030 | €7.39 | 21.55% |
2031 | €6.99 | 5.41% |
2032 | €7.53 | 7.73% |
Current | 19.31 | 7.25% |
---|---|---|
2025 | 11.29 | 41.54% |
2026 | 10.30 | 8.77% |
2027 | 8.78 | 14.76% |
2028 | 7.88 | 10.25% |
2029 | 7.12 | 9.64% |
2030 | 5.85 | 17.84% |
2031 | 6.19 | 5.81% |
2032 | 5.75 | 7.11% |
Based on analysts' sales estimates for 2025, the Fresenius Medical Care stock is valued at an EV/Sales of 1.08 and an P/S ratio of 0.64 .
This results in the following potential growth metrics and future valuations:
Current | 1.09 | 0.91% |
---|---|---|
2025 | 1.08 | 0.61% |
2026 | 1.05 | 3.01% |
2027 | 1.01 | 4.25% |
2028 | 0.95 | 5.17% |
2029 | 0.91 | 4.30% |
2030 | 0.86 | 5.99% |
2031 | 0.85 | 1.05% |
2032 | 0.82 | 3.44% |
Current | 0.64 | 12.77% |
---|---|---|
2025 | 0.64 | 1.04% |
2026 | 0.62 | 3.01% |
2027 | 0.59 | 4.25% |
2028 | 0.56 | 5.18% |
2029 | 0.54 | 4.29% |
2030 | 0.50 | 5.99% |
2031 | 0.50 | 1.03% |
2032 | 0.48 | 3.45% |
Fresenius Medical Care...
Analyst | Rating | Action | Date |
---|---|---|---|
JEFFERIES |
Underperform
➜
Underperform
|
Unchanged | Sep 15 2025 |
BERENBERG |
Buy
➜
Buy
|
Unchanged | Sep 11 2025 |
LANDESBANK BADEN-WUERTTEMBERG |
Hold
➜
Buy
|
Upgrade | Aug 29 2025 |
METZLER EQUITIES |
Buy
➜
Buy
|
Unchanged | Aug 29 2025 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Aug 18 2025 |
ODDO BHF |
Buy
➜
Buy
|
Unchanged | Aug 08 2025 |
INTESA SANPAOLO EQUITY RESEARCH |
Hold
➜
Buy
|
Upgrade | Aug 08 2025 |
Analyst Rating | Date |
---|---|
Unchanged
JEFFERIES:
Underperform
➜
Underperform
|
Sep 15 2025 |
Unchanged
BERENBERG:
Buy
➜
Buy
|
Sep 11 2025 |
Upgrade
LANDESBANK BADEN-WUERTTEMBERG:
Hold
➜
Buy
|
Aug 29 2025 |
Unchanged
METZLER EQUITIES:
Buy
➜
Buy
|
Aug 29 2025 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Aug 18 2025 |
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Aug 08 2025 |
Upgrade
INTESA SANPAOLO EQUITY RESEARCH:
Hold
➜
Buy
|
Aug 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.